Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Singapore-based biotechnology company S*BIO has granted a worldwide exclusive license to Tragara Pharmaceuticals, a developer of drugs for the treatment of cancer and inflammation-related diseases, to develop and commercialize its novel multi-kinase inhibitor SB1317.
Subscribe to our email newsletter
Under the terms of the agreement S*BIO is eligible to receive up to $112.5 million in payments. This includes an upfront fee, development and sales milestone payments and up to double-digit royalties.
Additionally, S*BIO will perform certain preclinical activities for Tragara under a defined workplan in return for research fees. Tragara is responsible for all investigational new drug (IND) enabling, development and commercialization activities under the agreement.
SB1317 is a novel orally-available, multi-kinase inhibitor with excellent pharmacological and pharmaceutical properties. SB1317 development will be initially focused on the treatment of hematologic malignancies and Tragara will also explore the therapeutic potential of the compound’s activity in solid tumors.
Jan-Anders Karlsson, CEO of S*BIO, said: We are pleased to work with Tragara in rapidly advancing SB1317 through IND enabling studies to the clinic. We chose Tragara as a partner due to a combination of their experience, exciting clinical development plans and commitment to speed.
Together we will determine the full breadth of the compound’s competitive advantages in a series of preclinical profiling studies prior to Tragara advancing this product through parallel tracks of clinical development.